Celltrion Celebrates Interchangeability Designation For Humira Biosimilar In The US

Also, Biosimilar Approvals In Australia And Supply Bids In Latin America

 
• By Urtė Fultinavičiūtė

Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.

Logo of the US Food and Drug Administration
(Shutterstock)

The US Food and Drug Administration has deemed Celltrion’s Yuflyma (adalimumab-aaty) as interchangeable with the originator Humira.

The interchangeability designation comes almost two years after Yuflyma received approval in the US in May 2023.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Generics Bulletin